The DPO Centre

The secondary use of health data is becoming one of the biggest drivers of innovation across clinical research. But as AI technology advances and EU and UK regulations evolve, CROs and sponsors need to think ahead about how trial data might be used, or reused, in the future. 

Join session moderator Ben Seretny, COO at The DPO Centre, alongside Lawrence Carter, DPO and Life Sciences Sector Lead, and Pippa Scotcher, DPO, for a forward-looking discussion on how AI and diverging governance frameworks are likely to impact the future of secondary data use and informed consent in clinical trials. 

You’ll learn: 

*   How EU and UK regulatory reforms are reshaping secondary use of data 
*   The growing role of AI in expanding the value and risk of health data reuse 
*   What this means for informed consent and site-level secondary data use 
*   Practical steps CROs and sponsors can take to prepare for evolving governance and ethical requirements 

This session will close with an open Q\&A discussion, with practical insights on how to stay compliant, future-ready and confident as AI redefines the boundaries of research data. 
